PUMA BIOTECHNOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 55.88K shares, a 12.85% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 64.12K shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- PUMA BIOTECHNOLOGY, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | 55.88K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 55.88K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 55.88K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 55.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 120.00K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | 64.12K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 64.12K shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 64.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 64.12K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 0.00 shares 10-K · filed 2026-02-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 0.00 shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-02 | 0.00 shares derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 0.00 shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 0.00 shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-04 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 0.00 shares 10-K · filed 2024-02-29 |
| 2020-12-31 | 6.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | 18.20K shares 10-K · filed 2023-03-02 |
| 2020-09-30 | 11.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 12.00K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 20.50K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | 500.00 shares 10-Q · filed 2020-05-07 | 32.00K shares derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 87.63K shares 10-K · filed 2022-03-03 |
| 2019-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 100.61K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | 11.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | 105.66K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | 56.13K shares 10-Q · filed 2019-05-10 | 184.30K shares derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | 12.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 200.74K shares 10-K · filed 2021-03-01 |
| 2018-09-30 | 25.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 325.33K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | 90.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 588.29K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | 72.57K shares 10-Q · filed 2018-05-10 | 596.18K shares derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | 137.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | 557.08K shares 10-K · filed 2020-02-28 |
| 2017-09-30 | 288.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 427.00K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | 98.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | 149.00K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | 33.47K shares 10-Q · filed 2017-05-10 | 50.97K shares derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | 7.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | 43.75K shares 10-K · filed 2019-03-01 |
| 2016-09-30 | 10.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | 73.03K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | 273.36K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | 26.25K shares 10-Q · filed 2016-05-10 | 396.93K shares derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | 36.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | 757.04K shares 10-K · filed 2018-03-09 |
| 2015-09-30 | 210.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | 1.15M shares derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | 123.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | |
| 2015-03-31 | 386.36K shares 10-Q · filed 2015-05-11 | |
| 2014-12-31 | 430.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | 430.49K shares 10-K · filed 2017-03-01 |
| 2013-12-31 | 314.62K shares 10-K · filed 2016-02-29 | |
| 2012-12-31 | 11.67K shares 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |